BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

SHA:688166 Revenue

BrightGene Bio-Medical Technology had revenue of 353.16M CNY in the quarter ending June 30, 2026, with 22.42% growth. This brings the company's total for the last twelve months to 1.36B, up 17.38% year-over-year. In the year 2025, BrightGene Bio-Medical Technology had annual revenue of 1.22B, down -4.59%. That makes BrightGene Bio-Medical Technology the 17,335th largest company in the world by revenue and 3,139th in China.

• Revenue (ttm): 1.36B
• Revenue Growth: +17.38%
• P/S Ratio: 9.79
• Revenue / Employee: 1.14M
• Employees: 1,199
• Market Cap: 13.36B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Income from sale of Products 1.08B 90.7%
• Equity Share Income 66.07M 5.6%
• Income from Technology 44.46M 3.7%

By Geography

Chart

• China 669.79M 56.3%
• Export 519.71M 43.7%

Fiscal year ended Dec 31, 2025 See the full SHA:688166 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.22B	-58.91M	-4.59%
Dec 31, 2024	1.28B	103.03M	8.74%
Dec 31, 2023	1.18B	162.19M	15.94%
Dec 31, 2022	1.02B	-35.08M	-3.33%
Dec 31, 2021	1.05B	267.03M	34.00%

Data Source: S&P Global Market Intelligence Last updated: Aug 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 21, 2026

Data Sources Report a data error